1-9 of 9
Lisa J McGarry, MPH
Close
Sort by
Journal Articles

A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia

Elias J. Jabbour, MD, Maral DerSarkissian, PhD, Mei Sheng Duh, Nora McCormick, MSc, Wendy Y. Cheng, MPH, MPhil, Lisa J. McGarry, MPH, Ariadne Souroutzidis, BA, Hui Huang, PhD MBA, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 5189.
https://doi.org/10.1182/blood.V128.22.5189.5189
Published: 2016
Journal Articles

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Hui Huang, PhD MBA
Journal: Blood
Blood (2016) 128 (22): 3081.
https://doi.org/10.1182/blood.V128.22.3081.3081
Published: 2016
Journal Articles

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Moshe Yair Levy, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Mo Yang, PhD, Frank G. Haluska, MD
Journal: Blood
Blood (2015) 126 (23): 1588.
https://doi.org/10.1182/blood.V126.23.1588.1588
Published: 2015
Journal Articles

Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Mo Yang, PhD, Stephanie Lustgarten, PhD, Hui Huang, MBA, PhD
Journal: Blood
Blood (2015) 126 (23): 1591.
https://doi.org/10.1182/blood.V126.23.1591.1591
Published: 2015
Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 480.
https://doi.org/10.1182/blood.V126.23.480.480
Published: 2015
Journal Articles

Comparative Efficacy Among 3 rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors

Jeffrey H. Lipton, MD PhD, Dhvani Shah, MS, Vanita Tongbram, MBBS, MPH, Manpreet K Sidhu, BA, PhD MBA, Hui Huang, PhD MBA, Lisa J McGarry, MPH, Stephanie Lustgarten, PhD, Neil Hawkins, PhD
Journal: Blood
Blood (2014) 124 (21): 4551.
https://doi.org/10.1182/blood.V124.21.4551.4551
Published: 2014
Journal Articles

Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

Moshe Yair Levy, MD, Lisa J McGarry, MPH, Hui Huang, PhD MBA, Stephanie Lustgarten, PhD, Christopher Nieset, PharmD, Frank G Haluska
Journal: Blood
Blood (2014) 124 (21): 3154.
https://doi.org/10.1182/blood.V124.21.3154.3154
Published: 2014
Journal Articles

Real-World Prescribing Patterns with Ponatinib Among New and Ongoing US Patients

Lisa J McGarry, MPH, Greg Wolfe, PharmD, Ann Steagall, BSN, RN, OCN, Hui Huang, PhD MBA
Journal: Blood
Blood (2014) 124 (21): 5521.
https://doi.org/10.1182/blood.V124.21.5521.5521
Published: 2014
Journal Articles

Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).

Lisa J McGarry, MPH, Chakkarin Burudpakdee, PharmD, Smeet Gala, MS, Arpamas Seetasith, PhD, Merena Nanavaty, MS, Hui Huang, PhD MBA
Journal: Blood
Blood (2014) 124 (21): 5524.
https://doi.org/10.1182/blood.V124.21.5524.5524
Published: 2014